Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02518464 · ClinicalTrials.gov registry record · Phase 4
Ticagrelor Therapy for RefrACTORy Migraine Study
A Phase 4 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
NCT02518464 is a Phase 4 study that has completed, run by Columbia University. The registered enrollment target is 40 participants.
The verdict
NCT02518464, a Phase 4 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a prospective, open-label, single-arm pilot study treating 40 subjects to assess the hypothesis that P2Y, G protein-coupled 12 (P2Y12) inhibition with Brilinta/ticagrelor (90 mg by mouth (PO) twice a day) reduces episodic and/or chronic migraine headache symptoms in patients with right to left shunt. Headache frequency while on Brilinta/ticagrelor will be compared with the documented baseline for each subject. If the Brilinta/ticagrelor therapy was effective (\> 50% reduction in monthly headache days), the subject could elect to continue therapy for an additional two months (56 days), while continuing to complete daily headache logs.
Interventions
- DRUG Ticagrelor 90 mg twice per day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02518464
The ClinicalTrials.gov registry entry for NCT02518464 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ticagrelor 90 mg twice per day is the first listed.
NCT02518464 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02518464 about?
NCT02518464 is a clinical study titled "Ticagrelor Therapy for RefrACTORy Migraine Study". This is a prospective, open-label, single-arm pilot study treating 40 subjects to assess the hypothesis that P2Y, G protein-coupled 12 (P2Y12) inhibition with Brilinta/ticagrelor (90 mg by mouth (PO) twice a day) reduces episodic and/or chronic migraine headache symptoms in patients with right to le...
What is the current status of trial NCT02518464?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2015-10. Estimated completion is 2017-10.
What interventions are being tested in trial NCT02518464?
The interventions under investigation include: Ticagrelor 90 mg twice per day (DRUG).
Who is sponsoring clinical trial NCT02518464?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.